Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | genetic association 0.42 (overall 0.26) | 0.42 |
| cell type Human Protein Atlas | cell type enhanced in brain inhibitory neurons (199 nCPM) | 1.00 |
| chemistry Open Targets | reachable by antibody | 0.45 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 1 pathway; mostly lysosome and autophagy | 1.00 |
Knock down and overexpress PLPPR4 in dopamine neurons; measure glucocerebrosidase (GCase) activity and LC3-II and p62 flux and survival of TH-positive neurons and phospho-α-synuclein (pS129) inclusions after seeding with α-synuclein fibrils.
- Cell type
- dopamine neurons
- Direction
- Both arms: public data does not say which way helps.
- Molecular readout
- glucocerebrosidase (GCase) activity and LC3-II and p62 flux
- Functional readout
- survival of TH-positive neurons and phospho-α-synuclein (pS129) inclusions after seeding with α-synuclein fibrils
- Rule-out
- If neither arm moves glucocerebrosidase (GCase) activity by 20% or more against non-targeting and empty-vector controls, across three independent differentiations, the hypothesis is wrong.
- Lab request
- CRISPRi knockdown and lentiviral overexpression of PLPPR4 in iPSC-derived midbrain dopamine neurons (FOXA2+, LMX1A+, TH+); n = 3 differentiations; readouts: glucocerebrosidase (GCase) activity and LC3-II and p62 flux; survival of TH-positive neurons and phospho-α-synuclein (pS129) inclusions after seeding with α-synuclein fibrils. Controls: non-targeting guide, empty vector. About 8 to 10 weeks, most of it differentiation.
Sealed predictions
- PLPPR4 in dopamine neurons, braak+0.04 (p 0.926) → +0.27 (p 0.474)receipt 1644
Swarm cases
receipt 1644: PLPPR4 in dopamine neurons, braak
- power
- full sample +0.21 (p 0.408, n 18), 95% CI -0.29 to +0.61. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.21 (p 0.408, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.21 (p 0.413, n 18). could be the mix.
- skeptic
- leave-one-out range +0.10 to +0.37, sign flips 0; without severely affected donors +0.21 (p 0.408, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for PLPPR4 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts